• The agreement includes two clinical stage molecules for schizophrenia and movement disorders and MIJ821, a clinical stage molecule previously licensed exclusively by Novartis for addressing treatment-resistant depression.

• The deal builds on Novartis expertise in neuroscience and advances the company’s development of potential neuropsychiatric medicines.
• The planned acquisition reflects the Novartis commitment to reimagining neuroscience by bringing potentially transformative therapies to patients who suffer from severe, …